Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222509 | 0.92 | PTGDR2 (0.40) | PTGDR2MTNR1AMTNR1BHTR6PTGDR | |
| SCHEMBL18239791 | 0.92 | PTGDR2 (0.40) | PTGDR2MTNR1AHTR6PTGDRPLA2G4A | |
| SCHEMBL18239708 | 0.88 | PTGDR2 (0.40) | PTGDR2MTNR1AMTNR1BNQO2PTGDR | |
| SCHEMBL18239857 | 0.85 | PTGDR2 (0.44) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18222515 | 0.85 | PTGDR2 (0.48) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18239789 | 0.85 | PTGDR2 (0.46) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18239688 | 0.83 | HTR6 (0.45) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18239831 | 0.82 | MAPT (0.44) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18239754 | 0.82 | HTR6 (0.57) | PTGDR2MTNR1AMTNR1BNQO2HTR6 | |
| SCHEMBL18800006 | 0.81 | MTNR1A (0.45) | MTNR1AMTNR1BNQO2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3095781-A1 | INDOLE COMPOUND | Astellas Pharma Inc. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | PTGDR2 86/4885MTNR1A 1/4885MTNR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.